Paul Hudson, AP Images

Sanofi and GSK grab largest Warp Speed deal yet, se­cur­ing $2.1B for a vac­cine that might come next year

Sanofi and Glax­o­SmithK­line have be­come the lat­est mem­bers of Op­er­a­tion Warp Speed, land­ing a $2.1 bil­lion con­tract to scale up man­u­fac­tur­ing for a vac­cine that is on track for com­ple­tion next year. The deal se­cures the US 100 mil­lion dos­es, with an op­tion for 500 mil­lion more.

It is the largest con­tract the White House has giv­en yet in its hunt to make 300 mil­lion dos­es of a vac­cine avail­able to the US pub­lic by Jan­u­ary, al­though Sanofi has not com­mit­ted to sup­ply vac­cines by that time, po­ten­tial­ly open­ing the door for oth­er de­vel­op­ers with longer de­vel­op­ment paths to gain fund­ing. The cash will help Sanofi scale the vac­cine, which com­bines their re­com­bi­nant DNA tech­nol­o­gy with GSK’s im­mune-boost­ing ad­ju­vant, to a bil­lion dos­es next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.